Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor
CytoMed and SunAct will be the joint sponsors of the clinical trial.On Monday, CytoMed Therapeutics (NASDAQ:GDTC) stock is down 6.35% at $3.23 at last check Monday.
週一，CytoMed Therapeutics（納斯達克：GDTC）股票在最後一次檢查時下跌了6.35%，報3.23美元。
The Singapore-based clinical-stage biopharmaceutical entered into a five-year Business & Research Collaboration Agreement (BRCA) with India-based SunAct Cancer Institute Private.
這家總部位於新加坡的臨牀階段生物製藥公司與總部位於印度的SunAct癌症研究所簽訂了一項爲期五年的業務與研究合作協議（BRCA）。
The BRCA will explore the safety, tolerability, potency, and efficacy of CytoMed's proprietary allogeneic gamma delta T cells for various cancers (including solid tumors). The human clinical research trial includes a Phase 2 investigator-initiated trial in India.
BRCA將探索CytoMed專有的異源伽馬δT細胞在各種癌症（包括實體腫瘤）中的安全性、耐受性、有效性和效能。該人體臨牀研究試驗包括在印度進行的II期研究者主導試驗。
CytoMed and SunAct will be the joint sponsors of the clinical trial.
CytoMed和SunAct將共同贊助這項臨牀試驗。
"Initiating this research and undertaking the accelerated Clinical Trial in the form of a combined Phase 1 and Phase 2 Clinical Trial targets not just the safety and efficacy of the therapeutic application and intervention of allogeneic gamma delta T Cells in the treatment of solid cancers but also expedites the gathering of information and data on the initial safety, preliminary efficacy and optimal dosing. We expect to identify the types of cancers the therapy will work for, including the side effects of the same if any and how we might manage them," said Dr Vijay Patil.
「開展這項研究並加速進行結合I期和II期臨牀試驗的臨牀試驗，不僅針對異源伽馬δT細胞在實體癌症治療中的治療應用和干預的安全性和有效性，還加快了初步安全性、初步有效性和最佳劑量信息和數據的收集。我們預計將識別出該療法可有效治療的癌症類型，包括可能的副作用及其管理方法，」 Vijay Patil博士說道。
CytoMed chairman Peter Choo called the collaboration with SunAct "timely."
CytoMed主席Peter Choo稱與SunAct的合作「及時」。
According to the BRCA, CytoMed will provide scientific and technical assistance in planning and conducting the clinical trial.
根據BRCA，CytoMed將在規劃和進行臨牀試驗中提供科學和技術支持。
CytoMed will also be responsible for manufacturing the allogeneic gamma delta T cells as the investigational product.
CytoMed還將負責生產異源伽馬δT細胞作爲研究產品。
- ArcelorMittal South Africa To Cut 3,500 Jobs Amid Economic Struggles
- 南非阿塞洛米塔爾將在經濟困難中裁員3,500人
Image: Shutterstock
圖片：Shutterstock
